Simultaneous Inhibition of SIRT2 Deacetylase and Defatty-Acylase Activities via a PROTAC Strategy
- 21 September 2020
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (11) , 2305-2311
Abstract
As a member of the sirtuin family of enzymes, SIRT2 promotes tumor growth and regulates various biological pathways through lysine deacetylation and defatty-acylation. In the past few years, many SIRT2-selective small molecule inhibitors have been developed, but none have demonstrated simultaneous inhibition of both SIRT2 activities in cells. To further scrutinize the physiological importance and significance of SIRT2 deacetylase and defatty-acylase activities, small molecules that can selectively inhibit both activities of SIRT2 in living cells are needed. Here, we have applied the Proteolysis Targeting Chimera (PROTAC) strategy and synthesized a new SIRT2 inhibitor (TM-P4-Thal) to degrade SIRT2 selectively, which led to simultaneous inhibition of its deacetylase and defatty-acylase activities in living cells. Additionally, this compound exemplifies the advantage of the PROTAC strategy that allows complete eradication of an enzyme and its activity in biological settings.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK107868)
This publication has 37 references indexed in Scilit:
- Exploring Targeted Degradation Strategy for Oncogenic KRASG12CCell Chemical Biology, 2020
- Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of SirtuinJournal of Medicinal Chemistry, 2019
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cellsLeukemia, 2017
- A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein DegradationJournal of Medicinal Chemistry, 2017
- Deacylation Mechanism by SIRT2 Revealed in the 1′-SH-2′-O-Myristoyl Intermediate StructureCell Chemical Biology, 2017
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancerProceedings of the National Academy of Sciences, 2016
- A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer ActivityCancer Cell, 2016
- Kinetic and Structural Basis for Acyl-Group Selectivity and NAD+ Dependence in Sirtuin-Catalyzed DeacylationBiochemistry, 2015
- Sirtuin Inhibitors as Anticancer AgentsFuture Medicinal Chemistry, 2014
- The Biochemistry of SirtuinsAnnual Review of Biochemistry, 2006